009290 — Kwangdong Pharmaceutical Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapNeutral

Market Cap
KR₩275bn
Enterprise Value
KR₩410bn
Revenue
KR₩2tn

Annual income statement for Kwangdong Pharmaceutical Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	1,338,182	1,431,545	1,514,454	1,640,719	1,659,512
Cost of Revenue
Gross Profit	274,253	282,048	299,827	299,298	301,182
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	1,293,246	1,393,198	1,474,925	1,612,865	1,636,070
Operating Profit	44,936	38,347	39,529	27,854	23,442
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	34,329	36,291	49,019	57,325	30,985
Provision for Income Taxes
Net Income After Taxes	25,541	26,701	39,372	41,845	21,329
Minority Interest
Net Income Before Extraordinary Items
Net Income	24,019	24,174	36,966	40,481	20,968
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	24,032	24,174	36,966	40,481	20,968
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	583	584	1,003	997	520
Dividends per Share